

COUGH, COLDS, ALLERGY EXPERIENCE

After post-doctoral training in pharmacology at Yale University School of Medicine, Dr. Riker joined Richardson-Vicks in 1982 to become its Associate Director of Clinical Development. His focus was primarily, but not exclusively, on respiratory products specifically those indicated for cough & colds and allergy, such as Nyquil, Dayquil, Vicks 44, Sinex, etc. He also worked on analgesics and anti-histamines as they relate to colds including Aleve. His unit produced over 125 clinical trials during ten years including trials in support of claims, new technology evaluation, and disease progression. Many of these trials were done as academic collaborations with colds experts while others were done in-house; many were published and many remain proprietary. Much of this work was forward looking rather than current business support, for example evaluating the effects of intranasal steroids or naproxen on the common cold. He conducted trials of prevention as well as treatment and used models of natural colds and induced colds. All of his efforts related to product development and marketing of cough/colds products. Since leaving P&G in 2001 Dr. Riker was VP R&D & CSO at Chattem, managing all product development activities across multiple categories. Dr. Riker remains committed to OTC healthcare through his consulting practice, On Point Advisors, LLC (www.onptllc.com).

During his time at P&G Dr. Riker managed up to twelve people, one of whom, Ted Witek, later became a VP/R&D at Boehringer-Ingelheim. Together they built an in-house virology laboratory focused on respiratory viruses and an out-patient facility to support clinical testing. They worked closely with Jack Gwaltney, Fred Hayden, Ron Turner, Bob Naclerio, David Proud to name a few. Dr. Riker co-authored several key papers with these colleagues although beyond that Dr. Riker managed and designed the clinical protocols for many trials that were either not published or published under the academic authors' names. A scientific bibliography is available.

Dr. Riker is a member of the Infectious Disease Society of America, the American Academy of Asthma, Allergy, and Immunology, and the American Society of Clinical Pharmacology & Therapeutics among others. He was a member of the US OTC trade association's [CHPA] Scientific Affairs Committee from 2002-2007.